The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Background Of the side effects of prostaglandin analogues (PGAs), uveitis and cystoid macular oedema (CME) have significant potential for vision loss based on postmarket reports. Caution has been ...

AIMS/BACKGROUND Retinal vessel dilatation is a well known phenomenon in diabetes. In this study, the theory of whether excessive changes in diameter and length of retinal vessels occur in the ...

Credit: fizkes / Shutterstock. US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, ...

The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment. The open-label, dose-escalation trial will ...

Cystoid macular edema (CME) is a condition characterized by the accumulation of fluid in the macula, leading to swelling and potential vision impairment. This condition can occur as a side effect ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

This swelling can lead to serious vision problems ... following its 2021 approval for wet (neovascular) age-related macular degeneration. The ranibizumab injection (Lucentis) was first approved ...